Pay in 4 interest-free payments of $6.95 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
For Dihexa to progress in Alzheimer's research, several conditions would need to be met: Earlier intervention: Testing in cognitively normal individuals at high risk, or mild cognitive impairment, rather than established dementia Bioavailability optimization: Development of oral formulations with superior brain penetration, or better-tolerated intravenous regimens Combination approaches: Testing Dihexa alongside amyloid-targeting drugs or tau-focused therapeutics Mechanism refinement: Understanding which aspects of HGF signalling are beneficial versus which drive cancer risk concerns Patient stratification: Identifying subgroups (by genetics, biomarker status, disease stage) most likely to respond Dose optimization: The LIFT-AD trial used specific doses
- Ngoi ra cn cha cc thnh phn chit xut t nhin khc nh: chit xut rau m , lu , hoa hng ,
Available in doses of 3g, 5g, 8g, and 10g
Each has distinct profiles: HGH Fragment 176-191 is chemically similar to AOD 9604, being the same sequence without the added tyrosine
US$ 20.24
US$ 24.49
US$ 25.64
US$ 29.81
US$ 24.43
US$ 25.43
US$ 28.84
US$ 20.60
